New England Biolabs®, Inc. Launches Primer Monitor Tool for Tracking SARS-CoV-2 Variants That May Impact Primers Used in Diagnostic Assays

IPSWICH, Mass., June 10, 2021 /PRNewswire/ -- New England Biolabs (NEB^®), a leading supplier of reagents for the life sciences, today announced the launch of a web-based tool for monitoring the emergence of SARS-CoV-2 variants and their potential impact on COVID-19 diagnostic tests. The Primer Monitor Tool, which is updated regularly, provides simple visualization of known variants identified in the SARS-CoV-2 genome and offers insight into where commonly used or user-defined primer set assessment may be worthwhile.

As the SARS-CoV-2 virus has continued to spread and mutate, concerns have been raised about the effectiveness of current diagnostic tests to detect new strains of the virus. The U.S. Food and Drug Administration (FDA) issued guidance advising COVID-19 diagnostic developers to evaluate the impact of emerging and future SARS-CoV-2 variants on current diagnostic tests by routinely monitoring sequence alignment of primer/probe sequences with open access SARS-CoV-2 genomes databases such as GISAID, a global science initiative and primary source that provides open-access to genomic data of influenza viruses and the novel coronavirus responsible for COVID-19.

“With the issuance of the FDA guidance, we saw a need for creating an online tool for diagnostic researchers and developers that visualizes all of the SARS-CoV-2 genomic data and variant strains uploaded to the GISAID database,” said Steven Chiu, Product Marketing Manager, DNA Amplification, at NEB. “The tool is pre-loaded with commonly used primer sequences from SARS-CoV-2 qPCR and LAMP assays and ARTIC sequencing workflows (currently v3). Users can monitor those predefined primer sets as well as upload their own sequences of interest, with the option to subscribe and be alerted should variation cross a specified threshold in a geographic region of interest.”

More information can be found in this technical note, which is also available on neb.com. To access the tool, please visit https://primer-monitor.neb.com/

About New England Biolabs
Established in the mid 1970’s, New England Biolabs, Inc. (NEB) is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including molecular diagnostics development. New England Biolabs is a privately held company, headquartered in Ipswich, MA, and has extensive worldwide distribution through a network of exclusive distributors, agents and eight subsidiaries located in Australia, Canada, China, France, Germany, Japan, Singapore and the UK. For more information about New England Biolabs visit www.neb.com.

NEB^® and NEW ENGLAND BIOLABS^® are registered trademarks of New England Biolabs, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-england-biolabs-inc-launches-primer-monitor-tool-for-tracking-sars-cov-2-variants-that-may-impact-primers-used-in-diagnostic-assays-301310243.html

SOURCE New England Biolabs